Xponance Inc. Has $1.34 Million Stake in Exelixis, Inc. (NASDAQ:EXEL)

Xponance Inc. decreased its stake in Exelixis, Inc. (NASDAQ:EXEL) by 5.2% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 59,484 shares of the biotechnology company’s stock after selling 3,269 shares during the period. Xponance Inc.’s holdings in Exelixis were worth $1,337,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Fisher Asset Management LLC boosted its stake in Exelixis by 232.6% in the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 728 shares in the last quarter. Rise Advisors LLC acquired a new stake in Exelixis in the 1st quarter valued at $28,000. Park Place Capital Corp acquired a new stake in Exelixis in the 2nd quarter valued at $45,000. GAMMA Investing LLC boosted its stake in Exelixis by 107.9% in the 2nd quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 1,041 shares in the last quarter. Finally, EntryPoint Capital LLC boosted its stake in Exelixis by 537.2% in the 1st quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 1,746 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Insider Activity at Exelixis

In related news, CFO Christopher J. Senner sold 125,000 shares of the company’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $27.19, for a total value of $3,398,750.00. Following the completion of the sale, the chief financial officer now owns 721,680 shares in the company, valued at $19,622,479.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Exelixis news, EVP Dana Aftab sold 20,883 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $27.06, for a total value of $565,093.98. Following the completion of the transaction, the executive vice president now directly owns 500,107 shares of the company’s stock, valued at $13,532,895.42. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Christopher J. Senner sold 125,000 shares of the business’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $27.19, for a total value of $3,398,750.00. Following the completion of the transaction, the chief financial officer now directly owns 721,680 shares of the company’s stock, valued at $19,622,479.20. The disclosure for this sale can be found here. Over the last quarter, insiders sold 327,858 shares of company stock worth $8,640,129. 2.85% of the stock is owned by insiders.

Exelixis Stock Down 1.1 %

EXEL stock opened at $25.96 on Friday. The company has a market cap of $7.41 billion, a P/E ratio of 40.56, a PEG ratio of 0.56 and a beta of 0.54. Exelixis, Inc. has a twelve month low of $18.64 and a twelve month high of $27.83. The business has a fifty day moving average of $25.56 and a 200-day moving average of $23.48.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.44. The business had revenue of $637.18 million during the quarter, compared to the consensus estimate of $468.21 million. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. As a group, equities research analysts anticipate that Exelixis, Inc. will post 1.59 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $27.00 price objective on shares of Exelixis in a research report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $29.00 price objective on shares of Exelixis in a research report on Wednesday, September 18th. UBS Group assumed coverage on Exelixis in a research report on Thursday, September 19th. They issued a “neutral” rating and a $30.00 price objective for the company. Truist Financial reiterated a “buy” rating and issued a $33.00 price objective (up previously from $32.00) on shares of Exelixis in a research report on Thursday, August 8th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $29.00 price objective on shares of Exelixis in a research report on Tuesday, July 30th. Five investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $27.67.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.